Alvesco Side Effect Profile May Give Edge Among Corticosteroids
This article was originally published in Pharmaceutical Approvals Monthly
Aventis and Altana are hoping Alvesco’s similar rate of oropharyngeal side effects to placebo will help the agent penetrate the inhaled corticosteroid market.
You may also be interested in...
Aventis was the most prominent participant in the year-end NDA filing rush, submitting four applications: two new molecular entities, a vaccine and a new formulation.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011